GDC-0853|RG7845|BTK inhibitor

GDC-0853|RG7845|BTK inhibitor

GDC-0853 is orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.

Product Name: GDC-0853(RG7845)|Cat No: DC9942|cas: 1434048-34-6 |Other Names: GDC-0853,RG7845,GDC0853,RG 7845,GDC 0853,RG-7845

GDC-0853 is orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, GDC-0853 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.

For the research and scientific use only, not for human use!